aap reports first-half sales of EUR 16.3 million (+28%) and EBIT of EUR 1.7 million (+113%)

aap Implantate AG, a medical technology company listed on the Frankfurt Stock Exchange in the Prime Standard segment achieved in the first six months of the financial year 2008 a sales growth of 28% to EUR 16.3 million (first half of 2007: EUR 12.7 million) with an operating result/EBIT of EUR 1.7 million (first half of 2007: EUR 0.8 million) and a net income of EUR 0.9 million (+125%, first half of 2007: EUR 0.4 million).

With total assets of EUR 71.9 million (previous year: EUR 68.0 million) the equity ratio is currently 62.0%.

The sales growth was mainly achieved by the positive development of the trauma & orthopaedic segment of aap which increased its revenue by 80% from EUR 3.9 million to EUR 7.0 million – especially with international distributors and OEM-customers. For the bio implants segment, which increased its revenue from EUR 8.8 million to EUR 9.3 million, aap expects double digit growth rates during the second half of the year.

For 2008 aap anticipates a sales growth of more than 20% and an above-average increase in the company’s net income.

The publication of the full aap Implantate AG six-month report 2008 is scheduled for August 13, 2008 and will be available on www.aap.de.